<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201512023034N16</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-04-14</date_registration>
      <primary_sponsor>vice chancellor for Research, School of Nursing and Midwifery, Iran University  of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of  Counseling on Sexual Dysfunction of Women with Polycystic Ovarian Syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of Sexual Counseling on Sexual Dysfunction of Women with Polycystic Ovarian Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/3027</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Sexual Dysfunction.</hc_freetext>
      <i_freetext>Intervention 1: First, the Female sexual Function Index questionnaire (FSFI) will be completed by 80 patients with inclusion criteria  in the presence of researcher, individually . Then  randomely , patients will be divided into two groups, intervention  and control groups in the same time .Intervention for working group include four individual counseling sessions for 60 minutes’ consultations in accordance with PLISSIT model that will be carried out once a week by researcher. The first meeting after introduction and description of the goal of study, the first step (Permission) runs. At this stage, the patient will be allowed to speak about her sexual problems. At this stage, counseling techniques such as listening skills and pay attention to non-verbal gestures will be used and understood false beliefs and knowledge of patients and by collecting history and completed Sexual Function Index questionnaire, their problems will be diagnosised. At second session (Limited Information) which consultant will talk about the anatomy and physiology of the reproductive system and sexual cycle. In addition, explain about the disease, its side effects and its effect on sexual function and for a better understanding, slides and images color will be used. &#13;
Third session (Specific Suggestion) according to each patient by clients help, suggestions for remission of the disease will be done. For example,sensate focus technique,exersice, massage and etc, due to personal problem will be advised.&#13;
Last session (Intensive Therapy) is the final step. Patients who pass previous three sessions of counseling are suspected to any mental disorder, a history of rape and etc., will be referred to health professionals. &#13;
At the end of he each session, summery of that session, will be given to clients such as brochures and booklet.        &#13;
 Female Sexual Function Index questionnaire for working group, prior, immediately and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire will be completed. Intervention 2: At the end of intervention, training manual wich contains information about sexual responsive cycle, physiology and anatomy of the genital tract,  polycystic ovarian syndrome and its side effects, etc, prepared and will be presented for the control group.&#13;
 Female Sexual Function Index questionnaire for working group, prior, immediately and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire will be completed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fahimeh Golbabaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iran University of Medical Sciences, School of Nursing and Midwifery, Rashidyasemi St. , Valiasr St. , Tehran , Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8888 2885</telephone>
        <email>farnaz2006_1000@yahoo.com</email>
        <affiliation>School Nursing and Midwifery, Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Mansoureh Jamshidimanesh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iran University of Medical Sciences, School of Nursing and Midwifery, Rashidyasemi St. , Valiasr St. , Tehran , Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8888 2885</telephone>
        <email>Jamshidimanesh@yahoo.com</email>
        <affiliation>School Nursing and Midwifery, Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:&#13;
 Married; 18_45 years’ old; Iranian; Having at least degree of knowledge; Having sexual activity during past six months; The definitive diagnosis of the polycystic ovarian syndrome by a gynecologist and records in document which is based on the criteria of Rotterdam; Having sexual function score that is less than 28 before intervention; Lack of pregnancy and lactation and unwillingness to be pregnant during intervention; Lack of other acute physical and mental disease and endocrine disorder like thyroid disorders, diabetes based on the patient’s medical document; Lack of consumption alcohol and drugs by patients and her husband according to the patient’s&#13;
reports; Lack of consumption drugs that are effective on sexual activity like ant depression, antihypertensive drugs...; Lack of consumption of any drugs or hormonal intervention during the last 60 days before intervention; Lack of history of women surgery such as genital surgery and breast surgery; Lack of sexual dysfunction by patient’s husband (according to patients reports); Lack of participation in training classes to counseling for sexual dysfunction; Lack of stressful events that are unrelated to pregnancy&#13;
Exclusion criteria:&#13;
Missing one of the session; Occurrences of stressful events that are unrelated to pregnancy</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sexual dysfunction, not caused by organic disorder or disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First, the Female sexual Function Index questionnaire (FSFI) will be completed by 80 patients with inclusion criteria  in the presence of researcher, individually . Then  randomely , patients will be divided into two groups, intervention  and control groups in the same time .Intervention for working group include four individual counseling sessions for 60 minutes’ consultations in accordance with PLISSIT model that will be carried out once a week by researcher. The first meeting after introduction and description of the goal of study, the first step (Permission) runs. At this stage, the patient will be allowed to speak about her sexual problems. At this stage, counseling techniques such as listening skills and pay attention to non-verbal gestures will be used and understood false beliefs and knowledge of patients and by collecting history and completed Sexual Function Index questionnaire, their problems will be diagnosised. At second session (Limited Information) which consultant will talk about the anatomy and physiology of the reproductive system and sexual cycle. In addition, explain about the disease, its side effects and its effect on sexual function and for a better understanding, slides and images color will be used. &#13;
Third session (Specific Suggestion) according to each patient by clients help, suggestions for remission of the disease will be done. For example,sensate focus technique,exersice, massage and etc, due to personal problem will be advised.&#13;
Last session (Intensive Therapy) is the final step. Patients who pass previous three sessions of counseling are suspected to any mental disorder, a history of rape and etc., will be referred to health professionals. &#13;
At the end of he each session, summery of that session, will be given to clients such as brochures and booklet.        &#13;
 Female Sexual Function Index questionnaire for working group, prior, immediately and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire will be completed.</i_keyword>
      <i_keyword>At the end of intervention, training manual wich contains information about sexual responsive cycle, physiology and anatomy of the genital tract,  polycystic ovarian syndrome and its side effects, etc, prepared and will be presented for the control group.&#13;
 Female Sexual Function Index questionnaire for working group, prior, immediately and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire will be completed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Satisfication. Timepoint: Prior, immediatly and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire. Method of measurement: Female Sexual Function Index questionnaire.</prim_outcome>
      <prim_outcome>Arousal. Timepoint: Prior, immediatly and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire. Method of measurement: Female Sexual Function Index questionnaire.</prim_outcome>
      <prim_outcome>Lubrication. Timepoint: Prior, immediatly and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire. Method of measurement: Female Sexual Function Index questionnaire.</prim_outcome>
      <prim_outcome>Orgasm. Timepoint: Prior, immediatly and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire. Method of measurement: Female Sexual Function Index questionnaire.</prim_outcome>
      <prim_outcome>Desire. Timepoint: Prior, immediatly and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire. Method of measurement: Female Sexual Function Index questionnaire.</prim_outcome>
      <prim_outcome>Sexual Dysfunction. Timepoint: Prior, immediatly and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire. Method of measurement: Female Sexual Function Index questionnaire.</prim_outcome>
      <prim_outcome>Pain. Timepoint: Prior, immediatly and eight weeks after last session of counseling in working group and for control group, eight weeks after filling out the initial questionnaire. Method of measurement: Female Sexual Function Index questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>vice chancellor for Research, School of Nursing and Midwifery, Iran University  of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-03-04</approval_date>
        <contact_name>Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Next to the Milad Tower,Shahid Hemmat Highway, Tehran, Iran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
